No drugs are currently approved for Coronavirus Disease-2019 ([[COVID-19]]), although some have been tried. In view of recent studies and [[discussion]] on [[chloroquine]] and [[hydroxychloroquine]] (HCQ), Singh et al. aimed to review existing literature and relevant websites regarding these drugs and COVID-19, [[adverse]] effects related to [[drug]]s, and related [[guideline]]s.

They systematically searched the PubMed database up till March 21, 2020, and retrieved all the articles published on chloroquine and HCQ and COVID-19.

Two small human studies have been conducted with both these drugs in COVID-19, and have shown significant improvement in some parameters in patients with COVID-19.

Considering minimal risk upon use, a long experience of use in other diseases, cost-effectiveness and easy availability across [[India]], they proposed that both these drugs are worthy of fast track [[clinical trial]] for treatment, and maybe carefully considered for clinical use as experimental drugs. Since HCQ has been approved for the treatment of [[diabetes]] in [[India]], it should be further researched in [[diabetes]] and COVID-19, a subgroup where significant [[mortality]] has been shown
((Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and
hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A
systematic search and a narrative review with a special reference to India and
other developing countries. Diabetes Metab Syndr. 2020 Mar 26;14(3):241-246. doi:
10.1016/j.dsx.2020.03.011. [Epub ahead of print] PubMed PMID: 32247211.
)).